Opendata, web and dolomites

NeuroDeRisk SIGNED

Neurotoxicity De-Risking in Preclinical Drug Discovery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "NeuroDeRisk" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAT WIEN 

Organization address
address: UNIVERSITATSRING 1
city: WIEN
postcode: 1010
website: www.univie.ac.at

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Total cost 9˙752˙062 €
 EC max contribution 5˙331˙000 € (55%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2017-13-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2022-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAT WIEN AT (WIEN) coordinator 594˙450.00
2    ITA-SUOMEN YLIOPISTO FI (KUOPIO) participant 804˙900.00
3    FARMACEUTSKI FAKULTET UNIVERZITETAU BEOGRADU RS (BELGRADE) participant 696˙150.00
4    ALCEDIAG FR (PEYNIER) participant 583˙300.00
5    UNIVERSITE CLERMONT AUVERGNE FR (CLERMONT-FERRAND) participant 429˙400.00
6    A. PERSIDIS & SIA OE EL (ATHINA) participant 406˙800.00
7    ICETA INSTITUTO DE CIENCIAS, TECNOLOGIAS E AGROAMBIENTE DA UNIVERSIDADE DO PORTO PT (PORTO) participant 403˙500.00
8    UNIVERSITA DEGLI STUDI DI FIRENZE IT (Florence) participant 391˙500.00
9    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 372˙200.00
10    INTE:LIGAND SOFTWARE-ENTWICKLUNGS-UND CONSULTING GMBH AT (MARIA ENZERSDORF) participant 341˙400.00
11    UPPSALA UNIVERSITET SE (UPPSALA) participant 307˙400.00
12    ASTRAZENECA AB SE (SODERTAELJE) participant 0.00
13    FUJIFILM CELLULAR DYNAMICS INC US (MADISON WI) participant 0.00
14    MERCK SHARP & DOHME CORP US (WHITEHOUSE STATION NJ) participant 0.00
15    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
16    PFIZER LIMITED UK (SANDWICH) participant 0.00
17    SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT FR (Chilly Mazarin) participant 0.00
18    UCB BIOPHARMA SRL BE (BRUXELLES) participant 0.00

Map

 Project objective

The adverse effects of pharmaceuticals on the central or peripheral nervous systems are poorly predicted by the current in vitro and in vivo preclinical studies performed during Research and Development (R&D) process. Therefore, increasing the predictivity of the preclinical toolbox is a clear need, and would benefit to human volunteers/patients (safer drugs) and Pharmaceutical Industry (reduced attrition). By combining top level scientists in neurobiology/toxicology with successful software developers, the NeuroDeRisk | Neurotoxicity De-Risking in Preclinical Drug Discovery Consortium will aim at tackling three of the most challenging adverse effects: seizures, psychological/psychiatric changes, and peripheral neuropathies. Our approach will be global, starting with an in-depth evaluation of knowledge on mechanisms of neurotoxicity (biological pathways as well as chemical structures and descriptors, using in particular historical data). Then we will search for innovative tools, assays and studies covering in silico, in vitro and in vivo approaches. This will include in particular: molecular design platform, artificial intelligence, human induced pluripotent stem cells, blood-brain-barrier models, immunohistochemistry, transcriptomics, RNA editing biomarkers, video-monitoring and telemetry of animals, pharmacokinetics, etc. The last step will aim at combining these tools in an integrated platform for better risk-assessment and decision-points throughout R&D process, and thus better protection of human volunteers and patients.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEURODERISK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEURODERISK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

TRIC-TB (2019)

Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.

Read More  

FAIRplus (2019)

FAIRplus

Read More